Glucose restriction combined with chemotherapy decreases telomere length and cancer antigen‑125 secretion in ovarian carcinoma
Autor: | S Antoun, Eliane Nasser Ayoub, Georges Chahine, Roula Tahtouh, George Hilal, Mona Diab Assaf, David Atallah, M Moubarak |
---|---|
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Cancer Research Telomerase chemotherapy telomerase 03 medical and health sciences 0302 clinical medicine glucose restriction medicine Telomerase reverse transcriptase Protein kinase B Mechanistic target of rapamycin PI3K/AKT/mTOR pathway Cisplatin biology Chemistry Articles Transfection Telomere platinum-taxane escape cells 030104 developmental biology Oncology cancer antigen-125 030220 oncology & carcinogenesis Cancer research biology.protein medicine.drug |
Zdroj: | Oncology Letters |
ISSN: | 1792-1082 1792-1074 |
Popis: | Although chemotherapy is the standard treatment for ovarian cancer (OC), recent studies have focused on its coupling with hypoglycemic drugs to decrease glucose availability. Similarly to cancer antigen 125 (Ca-125), telomerase, the key protein for telomere lengthening, is overexpressed in 90% of OC cases. The aim of the present study was to investigate the effect of the combination of glucose restriction and chemotherapy on telomere length and Ca-125 secretion in OC cells. SKOV-3, OVCAR-3 and Igrov-1 cells were treated with 20 µM cisplatin and 100 nM paclitaxel for 48 h in three different glucose concentrations: i) 4.5 g/l, ii) 1 g/l and iii) 0.5 g/l. The same treatment was repeated once per week for 6 consecutive weeks. The surviving cells were considered platinum-taxane escape (PTES) cells. The expression levels of telomerase and Ca-125 in treated and PTES cells were quantified by qPCR, and Ca-125 secretion by ELISA. Telomere length was evaluated by qPCR according to the Cawthon method. The modulation of Ca-125 by telomerase was assessed using inhibitors, small interfering RNA and transfection with human telomerase reverse transcriptase (hTERT) vectors. The implication of phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K/Akt/mTOR) in Ca-125 modulation was investigated using specific inhibitors. An increase in hTERT and Ca-125 expression levels (range, 1.5–3 fold) was observed in short-term treated cells. However, an opposite effect was detected in PTES cells, where the rate of decrease in the expression levels of hTERT and Ca-125 reached 60% after treatment in 0.5 g/l glucose. Moreover, telomere length was decreased by 30% in cells treated with 0.5 g/l glucose. Inhibition of hTERT expression significantly decreased Ca-125 secretion, suggesting a potential modulation of Ca-125 by hTERT. The inhibition of the PI3K/Akt/mTOR pathway also decreased Ca-125 secretion; however, the effect of this treatment was not enhanced when coupled with telomerase inhibitors. In conclusion, the combination of chemotherapy and glucose restriction was observed to decrease Ca-125 secretion and telomerase expression leading to shortening in telomere length. Thus, decreasing glucose availability for OC cells during treatment may lead to a better clinical outcome and potentially improve the prognosis of patients with OC. |
Databáze: | OpenAIRE |
Externí odkaz: |